Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that young biopharmaceutical companies are developing promising novel therapies for the treatment of metabolic diseases. Among the elite group of emerging players are Amylin Pharmaceuticals, Alizyme, Isis Pharmaceuticals, Ligand Pharmaceuticals, and Metabolex.
According to the new report entitled Metabolic Diseases Pipeline Analysis: Focus on Dyslipidemia, Diabetes, and Obesity, Amylin Pharmaceuticals has already scored multiple successes with two new therapies for treating diabetes. Both have been approved by the FDA in 2005.
"Although the metabolic disease arena is already a multibillion-dollar market, there remains significant room for growth. A number of factors will continue to fuel this growth, including the increasing prevalence of obesity, type 2 diabetes, and lipid abnormalities (dyslipidemia)," said Donny Wong, Ph.D., analyst at Decision Resources, Inc. "Furthermore, we believe that the growing recognition of the benefits of treating these conditions early and aggressively will drive demand for more effective therapies. In turn, advances in the treatment of diabetes and dyslipidemia are making it possible to better control conditions such as metabolic syndrome and to lower cardiovascular risk."
About DR Pipeline Reports from Decision Resources
DR Pipeline Reports is a series of comprehensive reports that focuses on pharmaceutical and biotech company drug development and commercialization strategies. DR Pipeline Reports expose major players in a therapeutic market and, more importantly, shed light on the emerging players that could significantly impact the current market once their pipelines are launched.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/